Acute Leukemia Perspective

 
 
  • Acute Leukemia Takeaways From ASH 2015: New Agents   Dr Farhad Ravandi provides an overview of the highlights in acute myeloid leukemia and acute lymphoblastic leukemia from the 2015 American Society of Hematology Annual Meeting.
  • American Society of Hematology (ASH) 57th Annual Meeting Read clinically focused news coverage of key developments from ASHP 2015.
  • ASH CAR T-Cell Therapy at ASH 2015: What's Hot A preview of the most important research on CAR T-cell therapy at the ASH 2015 annual meeting.
  • Docetaxel in Prostate Cancer -- The Pendulum Swings Back Upfront use of docetaxel for prostate cancer has waxed and waned over the years, but recent studies have brought the agent back to the forefront.
  • What to Expect in Hematologic Malignancies   Dr Bruce Cheson previews the most important trials being presented at ASCO 2015 on Hodgkin's and non-Hodgkin's lymphoma, acute and chronic leukemia, and multiple myeloma.
  • 'Emperor' in Close-Up: A Talk With the Director   Dr Harold Burstein gets an oncologist's behind-the- cameras view of 'Cancer: The Emperor of All Maladies,' from Barak Goodman, director of the Ken Burns documentary.
  • Today's Cancer Research Pioneers More than 50 years after the introduction of chemotherapy, a new wave of researchers seek to radically advance cancer treatments.
  • Perils and Pluses of 'Compassionate Use'   When a person is dying, there may be lots of pressure to give access to drugs still in development. This happened during the recent Ebola outbreak. But there are serious pros and cons to doing this.
  • Telling Stories: Why I Went Into Oncology An oncology fellow at Duke University describes why she chose the field and discusses whether the reality lives up to her expectations.
  • The Year in Hematologic Malignancies Experts in hematologic malignancies comment on the most important developments and practice-changing clinical trials of 2014.
  • Have We Overlooked Palliative Care?   Palliative care is not just for patients in hospice, explains Dr. Diane Meier; good palliative care can help relieve the suffering of people with chronic or disabling illnesses.
  • CAR T Cells: A Look Under the Hood and Down the Road Lost your way in immunotherapy? Dr. Mark Adler provides clinicians a roadmap for navigating cancer immunotherapy and takes one of the most promising approaches -- CAR T cells -- for a test drive.
  • ASCO President on the Triumph of the Open Mind   Dr. James Holland, president of ASCO in 1976-1977, talks to Dr. Kathy Miller about the early days of oncology, the society, and the humanist passion that is a driving force for both.
  • Ancestry Data in Cancer: Predictive, Prognostic, or Both?   Dr. Maurie Markman considers how genetic ancestry data might be used to predict risk for cancer relapse and inform potential ways to mitigate that risk.
  • Off and On Again Story of Ponatinib in CML Dr. Michael Deininger reviews data from ASH 2013 on ponatinib in chronic myeloid leukemia, and discusses the drug's future in view of the recent FDA decision to suspend -- and reinstate -- approval.
  • Is Obinutuzumab the Drug to Watch in CLL? Drs. Cheson and Czuczman highlight data on obinutuzumab, ibrutinib, idelalisib, and emerging agents that are reshaping the leukemia and lymphoma landscape.
  • Top News From ASH 2013: Slideshow Highlights include new promise with CAR-engineered T-cells for leukemia and lymphoma, a potentially disease-modifying drug for myelofibrosis, and novel targeted therapies for CLL.
  • Risk for Leukemia After Breast Cancer A new study shows that younger women had the highest risk for myelodysplasia or acute myeloid leukemia after a diagnosis of breast cancer.
  • 18th Congress of the European Hematology Association (EHA) Read clinically focused news coverage of key developments from EHA 2013.
  • New Therapy Unleashes 'Serial Killer' Cells in Leukemia Adoptive immunotherapy is providing exciting preliminary results in leukemia patients. Leading researcher Dr. Carl June explains the therapy and its potential application to other cancers.